Simply CMT

Halfway Up the Stairs: How One Family Turned Heartbreak Into Hope

The idea to fundraise for CMTA didn’t start with a plan. It started with a...

CMTA-STAR Alliance Partner NMD Pharma Shares SYNAPSE-CMT Trial Update

New Phase 2a CMT trial results are in. NMD Pharma shares details.

When Early Testing Shows a Program Is Worth Continuing

Some research ideas reach a point where early testing answers an important question: Is this work worth continuing? For EverTree Bio, that moment came through early work using the CMTA Preclinical Toolbox.

Under the Microscope: Reproductive Choices in CMT

CMTA-STAR Under the Microscope graphic titled “Reproductive Choices in CMT,” presenting a patient-friendly overview of family planning options for people living with Charcot-Marie-Tooth disease.

For people living with Charcot-Marie-Tooth disease, decisions about family planning can raise complex and deeply personal questions. This Under the Microscope installment explores various reproductive options and family planning resources.

ACT-CMT: The Largest-Ever Study of CMT Opens [Casting] Call for More Participants

Participant undergoes clinical strength and reflex testing during a CMTA-supported ACT-CMT study visit, highlighting patient involvement in Charcot-Marie-Tooth research.

The largest CMT1A study is expanding. New participants needed, including healthy volunteers. You can move this research forward.

Particles on a Mission: Can Nanoparticles Solve One of CMT’s Largest Hurdles?

Can nanoparticles solve one of CMT’s largest hurdles? A team in Cyprus is testing nanoparticle “mail carriers” designed to deliver genetic therapies directly into Schwann cells.

What Can Long-Read Sequencing Reveal About CMT?

What happened when CMTA-supported scientists at University College London applied long-read sequencing to CMT cases that had no genetic confirmation for years?